{"id":"placebo-jyb1904","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL6068159","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a Phase 3 candidate from Jemincare, JYB1904 is undergoing late-stage clinical evaluation; however, detailed mechanistic information regarding its molecular target, drug class, and mode of action is not available in public databases. The placebo-controlled design is standard for efficacy and safety assessment at this stage.","oneSentence":"JYB1904 is an investigational therapeutic being evaluated in combination with placebo control in a Phase 3 trial, though its specific molecular mechanism is not publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:27:43.279Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07459452","phase":"PHASE2","title":"Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2026-04","conditions":"Perennial Allergic Rhinitis","enrollment":135},{"nctId":"NCT07220811","phase":"PHASE2","title":"Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy","status":"RECRUITING","sponsor":"RAPT Therapeutics, Inc.","startDate":"2025-10-22","conditions":"Ig-E Mediated Food Allergy","enrollment":100},{"nctId":"NCT07402213","phase":"PHASE3","title":"Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2026-03-31","conditions":"Chronic Spontaneous Urticaria","enrollment":180},{"nctId":"NCT06509334","phase":"PHASE2","title":"Trial of JYB1904 in Chronic Spontaneous Urticaria.","status":"RECRUITING","sponsor":"Jemincare","startDate":"2024-08-04","conditions":"Chronic Spontaneous Urticaria","enrollment":135},{"nctId":"NCT05449535","phase":"PHASE1","title":"Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Jemincare","startDate":"2022-05-07","conditions":"Healthy","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo+JYB1904 Injection"],"phase":"phase_3","status":"active","brandName":"Placebo+JYB1904","genericName":"Placebo+JYB1904","companyName":"Jemincare","companyId":"jemincare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}